The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 524 KB) and Technical Notes (PDF, 762 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 20.28
Cancer of the Oral Cavity and Pharynx (Invasive)
| Histologya | Oral Cavity and Pharynx |
Lip | Tongue | Salivary Gland | Floor of Mouth | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Count | Percent | Count | Percent | Count | Percent | Count | Percent | Count | Percent | |
| Epidermoid carcinomab (8051-8131) | 41,634 | 84.3% | 2,759 | 94.4% | 14,414 | 97.3% | 1,212 | 21.9% | 2,411 | 95.4% |
| Squamous cell carcinoma (8070-8078,8083-8084) | 40,643 | 82.3% | 2,645 | 90.5% | 14,168 | 95.6% | 1,160 | 20.9% | 2,385 | 94.4% |
| Adenocarcinomac | 5,033 | 10.2% | 116 | 4.0% | 223 | 1.5% | 3,392 | 61.2% | 83 | 3.3% |
| Other specific carcinomas d | 514 | 1.0% | - | - | 37 | 0.2% | 306 | 5.5% | - | - |
| Unspecified, Carcinoma, NOS (8010-8011,8020-8022) | 1,611 | 3.3% | - | - | 79 | 0.5% | 414 | 7.5% | - | - |
| Sarcoma and soft tissuee | 153 | 0.3% | - | - | 19 | 0.1% | 33 | 0.6% | - | - |
| Other specific typesf | 264 | 0.5% | 17 | 0.6% | 16 | 0.1% | 115 | 2.1% | - | - |
| Unspecified (8000-8005) | 183 | 0.4% | - | - | 33 | 0.2% | 70 | 1.3% | - | - |
| Total | 49,393 | 100.0% | 2,923 | 100.0% | 14,821 | 100.0% | 5,542 | 100.0% | 2,526 | 100.0% |
| Histologya | Gum and Other Mouth |
Nasopharynx | Oropharynx and Tonsil |
Hypopharynx | Other Oral Cavity and Pharynx |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Count | Percent | Count | Percent | Count | Percent | Count | Percent | Count | Percent | |
| Epidermoid carcinomab (8051-8131) | 5,360 | 80.9% | 1,717 | 62.4% | 10,307 | 97.5% | 2,712 | 96.9% | 742 | 89.1% |
| Squamous cell carcinoma (8070-8078,8083-8084) | 5,111 | 77.1% | 1,566 | 56.9% | 10,185 | 96.4% | 2,691 | 96.1% | 732 | 87.9% |
| Adenocarcinomac | 1,034 | 15.6% | 87 | 3.2% | 64 | 0.6% | 16 | 0.6% | 18 | 2.2% |
| Other specific carcinomasd | 42 | 0.6% | 39 | 1.4% | 41 | 0.4% | 21 | 0.8% | - | - |
| Unspecified, Carcinoma, NOS (8010-8011,8020-8022) | 57 | 0.9% | 843 | 30.6% | 121 | 1.1% | 35 | 1.3% | 35 | 4.2% |
| Sarcoma and soft tissuee | 31 | 0.5% | 34 | 1.2% | - | - | - | - | - | - |
| Other specific typesf | 86 | 1.3% | 16 | 0.6% | - | - | - | - | - | - |
| Unspecified (8000-8005) | 17 | 0.3% | 17 | 0.6% | 20 | 0.2% | - | - | - | - |
| Total | 6,628 | 100.0% | 2,753 | 100.0% | 10,568 | 100.0% | 2,799 | 100.0% | 833 | 100.0% |
Footnotes:
Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Percents may not sum to 100 due to rounding.
a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.
b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.
c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.
d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671
e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.
f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.
- Statistic not shown due to fewer than 16 cases during the time period.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.